Therapeutic options for Alzheimer's disease are currently limited to symptomatic treatment
that only provides modest and temporary maintenance of cognitive and memory functions …

Introduction: Alzheimer's disease (AD) is a daunting public health threat that has prompted
the scientific community's ongoing efforts to decipher the underlying disease mechanism …

Despite decades of intense research, therapeutics for Alzheimer's disease (AD) are still
limited to symptomatic treatments that possess only short-term efficacy. Recently, several …

It has now been~ 30 years since the Alzheimer's disease (AD) research entered what may
be termed the 'molecular era'that began with the identification of the amyloid β protein (Aβ) …

Worldwide multidisciplinary translational research has led to a growing knowledge of the
genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that …

Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mainly the memory
and cognitive function in elderly. Extracellular beta amyloid deposition and intracellular tau …

Alzheimer's disease (AD) is a neurodegenerative brain disorder that has an increasingly
large burden on health and social care systems. The pathophysiology involves the …

Alzheimer's disease (AD) is a major cause of morbidity in the elderly. AD affects over 5
million persons in the United States, but because it increases in incidence in the elderly, and …

Alzheimer's disease (AD) is a devastating neurodegenerative disorder resulting in cognitive
impairment, loss of executive functions and progressive dementia. AD is the most common …

Alzheimer's disease is the largest unmet medical need in neurology. Current drugs improve
symptoms, but do not have profound disease-modifying effects. However, in recent years …